Chimerism in Myeloid Malignancies following Stem Cell Transplantation Using FluBu4 with and without Busulfan Pharmacokinetics versus BuCy.
- Shatha Farhan,
- Michael Bazydlo,
- Klodiana Neme,
- Nancy Mikulandric,
- Edward Peres,
- Nalini Janakiraman
Adv Hematol 2017 8;2017:8690416. Epub 2017 Nov 8.
Stem Cell Transplant Program, Henry Ford Hospital, 2799 W. Grand Blvd, Detroit, MI 48202, USA.
In the era of precision medicine, the impact of personalized dosing of busulfan is not clear. We undertook a retrospective analysis of 78 patients with myeloid malignancies who received fludarabine and busulfan (FluBu4) with or without measuring Bu pharmacokinetics (Bu PK) and those who received busulfan with cyclophosphamide (BuCy). Fifty-five patients received FluBu4, of whom 21 had Bu PK measured, and 23 patients received BuCy. Read More